Femasys

About:

Femasys engages in R&D and manufacture of medical devices for women's healthcare.

Website: http://femasys.com

Top Investors: Salem Partners, PharmaCyte Biotech, Legacy Capital Partners, Mario Family Funds

Description:

Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.

Total Funding Amount:

$70.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Suwanee, Georgia, United States

Founded Date:

2004-01-01

Contact Email:

customerservice(AT)femasys.com

Founders:

Kathy Lee-Sepsick

Number of Employees:

11-50

Last Funding Date:

2023-11-15

IPO Status:

Public

Industries:

© 2025 bioDAO.ai